CSP Pharmacy Test with all Correct & 100% Verified Answers |Actual
Complete Update |Already Graded A+
A patient is started on Humira for HS. How should the patient be dosed?
a) 40 mg SC every 2 weeks
b) 160 mg SC once, then 80 mg on day 15, then 40 mg weekly on day 29
c) 160 mg SC once, then 80 mg on day 15, then 40 mg every 2 weeks on day 29
d) 80 mg SC once, then 40 mg every 2 weeks starting on day 8 - (ANSWER)b) 160 mg SC once, then 80
mg on day 15, then 40 mg weekly on day 29
Which biologic therapy is indicated to treat CAPS and FMF?
a) Actemra
b) Otezla
c) Spevigo
d) Ilaris - (ANSWER)d) Ilaris
A patient is being treated for CD with Tysabri infusions. At what point should therapy be discontinued if
no benefit is observed?
a) 12 weeks
b) 8 weeks
c) 6 weeks
d) 14 weeks - (ANSWER)a) 12 weeks
JK is a 50 year old male with past medical history of diabetes, seizure, arrhythmia, and prostate cancer.
He was diagnosed with rheumatoid arthritis and his provider is starting him on Rituxan. What monitoring
is required during infusion?
a) cardiac monitoring
b) IPIR
c) bleed monitoring
d) anaphylaxis - (ANSWER)a) cardiac monitoring
,CSP Pharmacy Test with all Correct & 100% Verified Answers |Actual
Complete Update |Already Graded A+
Which of the following medications has a boxed warning for myelosuppression?
a) Actemra
b) Otrexup
c) Rituxan
d) Lupkynis - (ANSWER)b) Otrexup
Which of the following conditions is Xeljanz FDA-approved to treat?
a) JIA
b) Chrohn's Disease
c) Psoriatic arthritis
d) nr-axSpA - (ANSWER)c) Psoriatic arthritis
A 45-year-old female patient (height: 5' 9", weight: 58 kg) is starting on Skyrizi for management of CD?
a) 45 mg SC at weeks 0 and 4, then every 12 weeks
b) 390 mg IV once, then 90 mg SC every 8 weeks
c) 600 mg IV at weeks 0, 4, 8, then 180-360 mg SC every 8 weeks starting week 12
d) 150 mg SC at weeks 0 and 4, then every 12 weeks - (ANSWER)c) 600 mg IV at weeks 0, 4, 8, then 180-
360 mg SC every 8 weeks starting week 12
Which of the following medications carries a risk for suicidal ideation?
a) Taltz
b) Adbry
c) Arcalyst
d) Otezla - (ANSWER)d) Otezla
, CSP Pharmacy Test with all Correct & 100% Verified Answers |Actual
Complete Update |Already Graded A+
A patient who was recently diagnosed with ankylosing spondylitis is initiating therapy but he would like
to trial a therapy with the least frequent injections. Which of the follow subcutaneous therapies do you
recommend?
a) Simponi
b) Actemra
c) Siliq
d) Benlysta - (ANSWER)a) Simponi
Which of the following is true of the JAK inhibitors?
a) They are first-line treatment for conditions such as rheumatoid arthritis and psoriatic arthritis
b) All of the oral JAK inhibitors carry the risk of leaving an inert shell in the stool
c) They require an EKG as part of baseline monitoring
d) They should be avoided at different hemoglobin cut-offs - (ANSWER)d) They should be avoided at
different hemoglobin cut-offs
Which of the following medications carries a boxed warning for anaphlaxis?
a) Rituxan
b) Rasuvo
c) Xolair
d) Entyvio - (ANSWER)c) Xolair
Which class of medications does Arcalyst belong to?
a) TNF inhibitors
b) IL-23 inhibitors
c) IL-17 inhibitors
d) IL-1 inhibitors - (ANSWER)d) IL-1 inhibitors
Complete Update |Already Graded A+
A patient is started on Humira for HS. How should the patient be dosed?
a) 40 mg SC every 2 weeks
b) 160 mg SC once, then 80 mg on day 15, then 40 mg weekly on day 29
c) 160 mg SC once, then 80 mg on day 15, then 40 mg every 2 weeks on day 29
d) 80 mg SC once, then 40 mg every 2 weeks starting on day 8 - (ANSWER)b) 160 mg SC once, then 80
mg on day 15, then 40 mg weekly on day 29
Which biologic therapy is indicated to treat CAPS and FMF?
a) Actemra
b) Otezla
c) Spevigo
d) Ilaris - (ANSWER)d) Ilaris
A patient is being treated for CD with Tysabri infusions. At what point should therapy be discontinued if
no benefit is observed?
a) 12 weeks
b) 8 weeks
c) 6 weeks
d) 14 weeks - (ANSWER)a) 12 weeks
JK is a 50 year old male with past medical history of diabetes, seizure, arrhythmia, and prostate cancer.
He was diagnosed with rheumatoid arthritis and his provider is starting him on Rituxan. What monitoring
is required during infusion?
a) cardiac monitoring
b) IPIR
c) bleed monitoring
d) anaphylaxis - (ANSWER)a) cardiac monitoring
,CSP Pharmacy Test with all Correct & 100% Verified Answers |Actual
Complete Update |Already Graded A+
Which of the following medications has a boxed warning for myelosuppression?
a) Actemra
b) Otrexup
c) Rituxan
d) Lupkynis - (ANSWER)b) Otrexup
Which of the following conditions is Xeljanz FDA-approved to treat?
a) JIA
b) Chrohn's Disease
c) Psoriatic arthritis
d) nr-axSpA - (ANSWER)c) Psoriatic arthritis
A 45-year-old female patient (height: 5' 9", weight: 58 kg) is starting on Skyrizi for management of CD?
a) 45 mg SC at weeks 0 and 4, then every 12 weeks
b) 390 mg IV once, then 90 mg SC every 8 weeks
c) 600 mg IV at weeks 0, 4, 8, then 180-360 mg SC every 8 weeks starting week 12
d) 150 mg SC at weeks 0 and 4, then every 12 weeks - (ANSWER)c) 600 mg IV at weeks 0, 4, 8, then 180-
360 mg SC every 8 weeks starting week 12
Which of the following medications carries a risk for suicidal ideation?
a) Taltz
b) Adbry
c) Arcalyst
d) Otezla - (ANSWER)d) Otezla
, CSP Pharmacy Test with all Correct & 100% Verified Answers |Actual
Complete Update |Already Graded A+
A patient who was recently diagnosed with ankylosing spondylitis is initiating therapy but he would like
to trial a therapy with the least frequent injections. Which of the follow subcutaneous therapies do you
recommend?
a) Simponi
b) Actemra
c) Siliq
d) Benlysta - (ANSWER)a) Simponi
Which of the following is true of the JAK inhibitors?
a) They are first-line treatment for conditions such as rheumatoid arthritis and psoriatic arthritis
b) All of the oral JAK inhibitors carry the risk of leaving an inert shell in the stool
c) They require an EKG as part of baseline monitoring
d) They should be avoided at different hemoglobin cut-offs - (ANSWER)d) They should be avoided at
different hemoglobin cut-offs
Which of the following medications carries a boxed warning for anaphlaxis?
a) Rituxan
b) Rasuvo
c) Xolair
d) Entyvio - (ANSWER)c) Xolair
Which class of medications does Arcalyst belong to?
a) TNF inhibitors
b) IL-23 inhibitors
c) IL-17 inhibitors
d) IL-1 inhibitors - (ANSWER)d) IL-1 inhibitors
